Pages that link to "Q42407761"

The following pages link to Francesca Romana Ponziani (Q42407761):

Displaying 37 items.

• Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications (Q26775927) (← links)
• What we should know about portal vein thrombosis in cirrhotic patients: a changing perspective (Q26827793) (← links)
• Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation (Q26852105) (← links)
• Diagnosis of bowel diseases: the role of imaging and ultrasonography. (Q30455406) (← links)
• Physiology and pathophysiology of liver lipid metabolism. (Q35662655) (← links)
• Diagnosis and treatment of small intestinal bacterial overgrowth (Q35860893) (← links)
• The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. (Q35973636) (← links)
• Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. (Q36009729) (← links)
• Management of hepatitis C virus infection recurrence after liver transplantation: an overview. (Q37844982) (← links)
• Use and indications of cholestyramine and bile acid sequestrants. (Q37899074) (← links)
• The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. (Q37950012) (← links)
• Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up (Q38192256) (← links)
• Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort (Q41175307) (← links)
• Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. (Q42230987) (← links)
• Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. (Q42407730) (← links)
• Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients (Q42977889) (← links)
• Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound (Q45719507) (← links)
• Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. (Q47738072) (← links)
• Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban (Q48154202) (← links)
• Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers (Q50550145) (← links)
• Hepatocellular Carcinoma is Associated with Gut Microbiota Profile and Inflammation in Non-Alcoholic Fatty Liver Disease. (Q53408592) (← links)
• Treatment of early stage chronic hepatitis C virus infection. (Q53705211) (← links)
• Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma (Q61045894) (← links)
• Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit† (Q62792207) (← links)
• Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications (Q88880467) (← links)
• Letter: improvement of clinical outcomes by metformin in metabolic liver disease-a microbiota-dependent mechanism? (Q92270735) (← links)
• Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study (Q92326187) (← links)
• Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease (Q92725480) (← links)
• Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma (Q92795035) (← links)
• Effect of liver transplantation on intestinal permeability and correlation with infection episodes (Q96692963) (← links)
• Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients (Q97093380) (← links)
• Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases (Q98173318) (← links)
• Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19 (Q98774540) (← links)
• Letter: liver involvement and mortality in COVID-19 patients - authors' reply (Q100443044) (← links)
• Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges (Q100542254) (← links)
• Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time? (Q114236738) (← links)
• Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy (Q125463678) (← links)